Exclude Patient Type Detail Header
No
Footnote
<sup>8</sup> Children most likely to benefit from immunoprophylaxis include: 1) infants w/ acyanotic heart dz on medication to control CHF and who will require cardiac surgical procedures; and 2) infants w/ mod to severe pulmonary HTN. Consult a pediatric cardiologist for decisions regarding prophylaxis for infants w/ cyanotic heart defects in the 1st yr of life.<br><br>
<sup>9</sup> The following groups of infants w/ CHD are not at increased risk of RSV infxn and generally should not receive immunoprophylaxis: 1) infants /children w/ hemodynamically insignificant heart dz (eg, secundum ASD, small VSD, pulmonic stenosis, mild coarctation of aorta, and PDA, 2) infants w/ lesions adequately corrected by surgery, unless medication for CHF still required, 3) infants w/ mild cardiomyopathy not on medical tx for the condition, and 4) children in the 2nd yr of life.
<br><br>
<sup>10</sup> Administer <b>palivizumab</b> 15 mg/kg IM monthly x5 mo max, or until end of RSV season, whichever comes first [B/M]. If breakthrough RSV infxn occurs, discontinue monthly palivizumab prophylaxis.
<br><br>
<sup>11</sup> If previous hospitalization for pulmonary exacerbation in the 1st yr of life, or abnormalities on chest radiography or chest CT that persist when stable.
<sup>9</sup> The following groups of infants w/ CHD are not at increased risk of RSV infxn and generally should not receive immunoprophylaxis: 1) infants /children w/ hemodynamically insignificant heart dz (eg, secundum ASD, small VSD, pulmonic stenosis, mild coarctation of aorta, and PDA, 2) infants w/ lesions adequately corrected by surgery, unless medication for CHF still required, 3) infants w/ mild cardiomyopathy not on medical tx for the condition, and 4) children in the 2nd yr of life.
<br><br>
<sup>10</sup> Administer <b>palivizumab</b> 15 mg/kg IM monthly x5 mo max, or until end of RSV season, whichever comes first [B/M]. If breakthrough RSV infxn occurs, discontinue monthly palivizumab prophylaxis.
<br><br>
<sup>11</sup> If previous hospitalization for pulmonary exacerbation in the 1st yr of life, or abnormalities on chest radiography or chest CT that persist when stable.
Detail Type
Text